Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relapsing-remitting

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    297 result(s) found for: Relapsing-remitting. Displaying page 15 of 15.
    «« First « Previous 7  8  9  10  11  12  13  14  15 
    EudraCT Number: 2020-003874-30 Sponsor Protocol Number: MS700568_0158 Start Date*: 2021-02-03
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial
    Medical condition: Highly-active relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) DK (Completed) AT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000893-69 Sponsor Protocol Number: BN42082 Start Date*: 2020-10-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS
    Medical condition: Relapsing Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000028-36 Sponsor Protocol Number: P3-IMU-838-RMS-01 Start Date*: 2022-04-21
    Sponsor Name:Immunic AG
    Full Title: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) BG (Trial now transitioned) GR (Completed) DE (Trial now transitioned) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003995-42 Sponsor Protocol Number: MS700568_0157 Start Date*: 2020-12-18
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A 2-year extension study to evaluate long-term effectiveness of Mavenclad® in participants who have completed Trial MS700568_0022 (MAGNIFY MS)
    Medical condition: Highly-active relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) FI (Completed) AT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003507-38 Sponsor Protocol Number: 218MS403 Start Date*: 2012-01-06
    Sponsor Name:Biogen Idec Research Limited
    Full Title: An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects with Multiple S...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) NL (Completed) PT (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007952-90 Sponsor Protocol Number: LT-02-UC-01 Start Date*: 2009-11-17
    Sponsor Name:Lipid Therapeutics GmbH
    Full Title: A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulce...
    Medical condition: Patients with ulcerative colitis (UC) according to European Crohn's and Colitis Organisation (ECCO) consensus; Simple Clinical Colitis Activity Index (SCCAI) ≥5 and SCCAI subscore for “blood in sto...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003465-38 Sponsor Protocol Number: MS-tolDC_Phase2-RESTORE Start Date*: 2023-05-08
    Sponsor Name:Antwerp University Hospital [...]
    1. Antwerp University Hospital
    2. Hospital Universitari Germans Trias i Pujol
    Full Title: A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for multiple sclerosis
    Medical condition: Diagnosis of multiple sclerosis, according to the most recent diagnostic criteria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000049-34 Sponsor Protocol Number: ACT16753 Start Date*: 2022-09-15
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long...
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) DE (Trial now transitioned) GR (Prematurely Ended) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000368-90 Sponsor Protocol Number: 218MS205 Start Date*: 2012-08-08
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004980-39 Sponsor Protocol Number: Amiloride02 Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis
    Medical condition: Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004589-32 Sponsor Protocol Number: 7724 Start Date*: 2014-05-07
    Sponsor Name:University of Southampton
    Full Title: Bath Additives for the Treatment of cHildhood Eczema (BATHE)
    Medical condition: Childhood Eczema
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10003641 Atopic eczema LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004158-40 Sponsor Protocol Number: P170702J Start Date*: 2018-09-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714
    Medical condition: Patients with Relapsing MS or primary progressive MS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000867-21 Sponsor Protocol Number: NGAM-13 Start Date*: 2021-08-16
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome
    Medical condition: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsio...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003361-14 Sponsor Protocol Number: LTS6050 Start Date*: 2007-01-23
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple...
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) FI (Completed) DE (Completed) IT (Completed) SE (Completed) NL (Completed) PT (Completed) DK (Completed) CZ (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003366-33 Sponsor Protocol Number: 26593 Start Date*: 2008-10-30
    Sponsor Name:MERCK SERONO INTERNATIONAL SA
    Full Title: A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris S...
    Medical condition: MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020881-53 Sponsor Protocol Number: 20100008 Start Date*: 2011-01-18
    Sponsor Name:Amgen Inc
    Full Title: A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10013099 Disease Crohns LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019544-39 Sponsor Protocol Number: 20090072 Start Date*: 2010-10-04
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn’s Disease
    Medical condition: Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10011408 Crohns disease aggravated LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 11 05:09:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA